1-17 of 17
Vlado Perkovic
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial

AKIHIKO KOSHINO, MEIR SCHECHTER, TAHA SEN, BRENDON NEUEN, CLARE ARNOTT, VLADO PERKOVIC, MICHAEL K. HANSEN, HIDDO L. HEERSPINK
Journal: Diabetes
Diabetes 2022;71(Supplement_1):862-P
https://doi.org/10.2337/db22-862-P
Published: 01 June 2022
View article titled, 862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial
Meeting Abstracts

747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial

RICHARD E. PRATLEY, FLORIAN M.M. BAERES, GEORGE BAKRIS, JACK LAWSON, KENNETH W. MAHAFFEY, JOHANNES F. MANN, HENRIETTE MERSEBACH, PETER ROSSING, KATHERINE R. TUTTLE, VLADO PERKOVIC
Journal: Diabetes
Diabetes 2022;71(Supplement_1):747-P
https://doi.org/10.2337/db22-747-P
Published: 01 June 2022
View article titled, 747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial
Meeting Abstracts

131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

JINLAN LIAO, AMY KANG, CHAO XIA, CLARE ARNOTT, GIAN LUCA DI TANNA, ARUN V. KRISHNAN, CAROL A. POLLOCK, RAJIV AGARWAL, GEORGE BAKRIS, HIDDO L. HEERSPINK, ADEERA LEVIN, DICK DE ZEEUW, BRUCE NEAL, HONG ZHANG, DAVID C. WHEELER, BERNARD ZINMAN, KENNETH W. MAHAFFEY, VLADO PERKOVIC, MEG J. JARDINE, BRENDAN SMYTH
Journal: Diabetes
Diabetes 2021;70(Supplement_1):131-LB
https://doi.org/10.2337/db21-131-LB
Published: 01 June 2021
View article titled, 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial
Meeting Abstracts

129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

TAE WON YI, BRENDAN SMYTH, AMY KANG, KATHRYN CARDOZA, GIAN LUCA DI TANNA, CLARE ARNOTT, CAROL A. POLLOCK, RAJIV AGARWAL, GEORGE BAKRIS, CHRISTOPHER P. CANNON, DICK DE ZEEUW, HIDDO L. HEERSPINK, ADEERA LEVIN, BRUCE NEAL, DAVID C. WHEELER, HONG ZHANG, BERNARD ZINMAN, KENNETH W. MAHAFFEY, VLADO PERKOVIC, MEG J. JARDINE, CREDENCE TRIAL INVESTIGATORS
Journal: Diabetes
Diabetes 2021;70(Supplement_1):129-LB
https://doi.org/10.2337/db21-129-LB
Published: 01 June 2021
View article titled, 129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial
Journal Articles

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Katherine R. Tuttle, Frank C. Brosius, III, Matthew A. Cavender, Paola Fioretto, Kevin J. Fowler, Hiddo J.L. Heerspink, Tom Manley, Darren K. McGuire, Mark E. Molitch, Amy K. Mottl, Leigh Perreault, Sylvia E. Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner, Vlado Perkovic
Journal: Diabetes
Diabetes 2021;70(1):1–16
https://doi.org/10.2337/dbi20-0040
Published: 26 October 2020
View article titled, SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Open the PDF for SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation in another window
Meeting Abstracts

139-LB: The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS

ELE FERRANNINI, SIMONA BALDI, TIZIANA SCOZZARO, FISSEHA TESFAYE, WAYNE SHAW, NORM ROSENTHAL, KENNETH W. MAHAFFEY, BRUCE NEAL, VLADO PERKOVIC, MICHAEL K. HANSEN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):139-LB
https://doi.org/10.2337/db20-139-LB
Published: 01 June 2020
View article titled, 139-LB: The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS
Meeting Abstracts

27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

JINGWEI LI, MEG J. JARDINE, BRUCE NEAL, HIDDO L. HEERSPINK, CHRISTOPHER CANNON, RAJIV AGARWAL, GEORGE BAKRIS, DAVID M. CHARYTAN, DICK DE ZEEUW, ROBERT EDWARDS, TOM GREENE, ADEERA LEVIN, CAROL A. POLLOCK, NORM ROSENTHAL, DAVID C. WHEELER, HONG ZHANG, BERNARD ZINMAN, VLADO PERKOVIC, KENNETH W. MAHAFFEY, CLARE ARNOTT
Journal: Diabetes
Diabetes 2020;69(Supplement_1):27-OR
https://doi.org/10.2337/db20-27-OR
Published: 01 June 2020
View article titled, 27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease
Meeting Abstracts

26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE

MEGUMI OSHIMA, MEG J. JARDINE, RAJIV AGARWAL, GEORGE BAKRIS, CHRISTOPHER CANNON, DAVID M. CHARYTAN, DICK DE ZEEUW, ROBERT EDWARDS, TOM GREENE, ADEERA LEVIN, KENNETH W. MAHAFFEY, BRUCE NEAL, CAROL A. POLLOCK, NORM ROSENTHAL, DAVID C. WHEELER, HONG ZHANG, BERNARD ZINMAN, VLADO PERKOVIC, HIDDO L. HEERSPINK
Journal: Diabetes
Diabetes 2020;69(Supplement_1):26-OR
https://doi.org/10.2337/db20-26-OR
Published: 01 June 2020
View article titled, 26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE
Meeting Abstracts

1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

JINGWEI LI, BRUCE NEAL, HIDDO L. HEERSPINK, CLARE ARNOTT, CHRISTOPHER CANNON, RAJIV AGARWAL, GEORGE BAKRIS, DAVID M. CHARYTAN, DICK DE ZEEUW, TOM GREENE, ADEERA LEVIN, RICHARD OH, CAROL A. POLLOCK, DAVID C. WHEELER, YSHAI YAVIN, HONG ZHANG, BERNARD ZINMAN, GIAN LUCA DI TANNA, VLADO PERKOVIC, KENNETH W. MAHAFFEY, MEG JARDINE
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1130-P
https://doi.org/10.2337/db20-1130-P
Published: 01 June 2020
View article titled, 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)
Meeting Abstracts

1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial

JINGWEI LI, TAHA SEN, BRUCE NEAL, BRENDON L. NEUEN, VLADO PERKOVIC, DICK DE ZEEUW, KENNETH W. MAHAFFEY, YSHAI YAVIN, NORM ROSENTHAL, MICHAEL K. HANSEN, HIDDO L. HEERSPINK
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1120-P
https://doi.org/10.2337/db20-1120-P
Published: 01 June 2020
View article titled, 1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial
Meeting Abstracts

1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial

TAHA SEN, JINGWEI LI, BRUCE NEAL, BRENDON L. NEUEN, MEG J. JARDINE, JOACHIM IX, MICHAEL G. SHLIPAK, VLADO PERKOVIC, YSHAI YAVIN, NORM ROSENTHAL, MICHAEL K. HANSEN, HIDDO L. HEERSPINK
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1098-P
https://doi.org/10.2337/db20-1098-P
Published: 01 June 2020
View article titled, 1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial
Meeting Abstracts

388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial

JULIO ROSENSTOCK, STEVEN E. KAHN, ODD ERIK JOHANSEN, MARK E. COOPER, NIKOLAUS MARX, JOHN H. ALEXANDER, ROBERT D. TOTO, CHRISTOPH WANNER, EGON PFARR, SVEN SCHNAIDT, JYOTHIS GEORGE, MAXIMILIAN VON EYNATTEN, DARREN K. MCGUIRE, VLADO PERKOVIC, BERNARD ZINMAN
Journal: Diabetes
Diabetes 2019;68(Supplement_1):388-P
https://doi.org/10.2337/db19-388-P
Published: 01 June 2019
View article titled, 388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial
Meeting Abstracts

432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease

NIKOLAUS MARX, DARREN K. MCGUIRE, ODD ERIK JOHANSEN, JULIO ROSENSTOCK, STEVEN E. KAHN, MARK E. COOPER, ROBERT D. TOTO, CHRISTOPH WANNER, EGON PFARR, SVEN SCHNAIDT, JYOTHIS GEORGE, MAXIMILIAN VON EYNATTEN, VLADO PERKOVIC, BERNARD ZINMAN, JOHN H. ALEXANDER
Journal: Diabetes
Diabetes 2019;68(Supplement_1):432-P
https://doi.org/10.2337/db19-432-P
Published: 01 June 2019
View article titled, 432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease
Meeting Abstracts

1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program

DAVID R. MATTHEWS, CAROL H. WYSHAM, MELANIE J. DAVIES, APRIL SLEE, MARIA ALBA, MARY LEE, GEORGE CAPUANO, VLADO PERKOVIC, KENNETH W. MAHAFFEY, BRUCE NEAL
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1206-P
https://doi.org/10.2337/db19-1206-P
Published: 01 June 2019
View article titled, 1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program
Meeting Abstracts

1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program

JINGWEI LI, SUNIL V. BADVE, ZIEN ZHOU, RICHARD OH, MARY LEE, VLADO PERKOVIC, DICK DE ZEEUW, KENNETH W. MAHAFFEY, GREG FULCHER, DAVID R. MATTHEWS, BRUCE NEAL
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1216-P
https://doi.org/10.2337/db19-1216-P
Published: 01 June 2019
View article titled, 1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program
Meeting Abstracts

Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes—The ADVANCE Trial

TOSHIAKI OHKUMA, MIN JUN, MARK WOODWARD, ESQ., JOHN CHALMERS, VLADO PERKOVIC, ANTHONY RODGERS
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1483-P
https://doi.org/10.2337/db18-1483-P
Published: 01 July 2018
View article titled, Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes—The ADVANCE Trial
Meeting Abstracts

Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease

BRENDON L. NEUEN, TOSHIAKI OHKUMA, BRUCE NEAL, DAVID R. MATTHEWS, KENNETH W. MAHAFFEY, GREG FULCHER, MEHUL DESAI, QIANG LI, HSIAOWEI DENG, NORM ROSENTHAL, MEG JARDINE, GEORGE BAKRIS, VLADO PERKOVIC
Journal: Diabetes
Diabetes 2018;67(Supplement_1):258-OR
https://doi.org/10.2337/db18-258-OR
Published: 01 July 2018
View article titled, Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease